Forside  
Velg data du ønsker med i utskriften
Tittel Versjon Status
IS-nr ISBN
Publiseringsdato
Utgiver(e) Publikasjonstype
  • Norsk tittel - Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppfølging av hode-/halskreft
  • Engelsk tittel -
  • Versjon - 1
  • Status - Publisert
  • IS-nr - 2907
  • ISBN - 978-82-8081-615-3
  • DOI -
  • Revisjonsdato -
  • Neste revisjon -
  • Publikasjonsdato - 06.05.2020
  • Utløpsdato -
  • Utgiver(e) - Helsedirektoratet
  • Redaktør -
  • Publikasjonstype - Nasjonale retningslinjer
 
  1. Larsen IK, red. Cancer in Norway 2016: cancer incidence, mortality, survival and prevalence in Norway. Oslo: Cancer Registry of Norway; 2017. Tilgjengelig fra: https://www.kreftregisteret.no/globalassets/cancer-in-norway/2016/cin-2106-070218.pdf 
  2. Guha N, Warnakulasuriya S, Vlaanderen J, Straif K. Betel quid chewing and the risk of oral and oropharyngeal cancers: a meta-analysis with implications for cancer control. Int J Cancer 2014;135(6):1433-43.
  3. Hui EP, Chan ATC. Epidemiology, etiology, and diagnosis of nasopharyngeal carcinoma. UpToDate [Database]. Waltham, MA: UpToDate, Inc [oppdatert 5. februar 2018; lest 14. februar 2018].
  4. DeSantis C, Naishadham D, Jemal A. Cancer statistics for African Americans, 2013. CA Cancer J Clin 2013;63(3):151-66.
  5. Larsen IK, red. Cancer in Norway 2014: cancer incidence, mortality, survival and prevalence in Norway. Oslo: Cancer Registry of Norway; 2015. Tilgjengelig fra: https://www.kreftregisteret.no/globalassets/cancer-in-norway/2014/cin2014-special_issue.pdf 
  6. Wyss A, Hashibe M, Chuang SC, Lee YC, Zhang ZF, Yu GP, et al. Cigarette, cigar, and pipe smoking and the risk of head and neck cancers: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. Am J Epidemiol 2013;178(5):679-90.
  7. Helserisiko ved bruk av snus. Oslo: Folkehelseinstituttet; 2014. Tilgjengelig fra: https://www.fhi.no/globalassets/dokumenterfiler/moba/pdf/helserisiko-ved-bruk-av-snus-pdf.pdf 
  8. Smokeless tobacco and some tobacco-specific N-Nitrosamines. Lyon: WHO og IARC; 2007. IARC Monographs on the evaluation of carcinogenic risks to humans, Volume 89.
  9. Alcohol drinking. Lyon: WHO og IARC; 1988. IARC Monographs on the evaluation of carcinogenic risks to humans, Volume 44.
  10. Blons H, Laurent-Puig P. TP53 and head and neck neoplasms. Hum Mutat 2003;21(3):252-7.
  11. Biolchini F, Pollastri G, Figurelli S, Chiarini L. Carcinogen metabolism, DNA damage repair and oral head and neck squamocellular carcinoma (HNSCC). A review. Minerva Stomatol 2005;54(7-8):405-14.
  12. Rosenquist K, Wennerberg J, Schildt EB, Bladstrom A, Goran Hansson B, Andersson G. Oral status, oral infections and some lifestyle factors as risk factors for oral and oropharyngeal squamous cell carcinoma. A population-based case-control study in southern Sweden. Acta Otolaryngol 2005;125(12):1327-36.
  13. Torjussen W. Nickel as carcinogenic factor in nasal carcinoma [proceedings]. Acta Otolaryngol Suppl 1979;360:125.
  14. Gordon I, Boffetta P, Demers PA. A case study comparing a meta-analysis and a pooled analysis of studies of sinonasal cancer among wood workers. Epidemiology 1998;9(5):518-24.
  15. Boysen M, Loven JO. Second malignant neoplasms in patients with head and neck squamous cell carcinomas. Acta Oncol 1993;32(3):283-8.
  16. Braakhuis BJ, Tabor MP, Leemans CR, van der Waal I, Snow GB, Brakenhoff RH. Second primary tumors and field cancerization in oral and oropharyngeal cancer: molecular techniques provide new insights and definitions. Head Neck 2002;24(2):198-206.
  17. Biological agents: a review of human carcinogens. Lyon: IRAC; 2012. IARC Monographs on the Evaluation of Carcinogenic Risk to Humans, Volume 100 B. Tilgjengelig fra: https://monographs.iarc.fr/iarc-monographs-on-the-evaluation-of-carcinogenic-risks-to-humans-20/ 
  18. Human papillomaviruses. Lyon: IRAC; 2007. IARC Monographs on the Evaluation of Carcinogenic Risk to Humans, Volume 90. Tilgjengelig fra: https://monographs.iarc.fr/iarc-monographs-on-the-evaluation-of-carcinogenic-risks-to-humans-31/ 
  19. Rautava J, Syrjanen S. Biology of human papillomavirus infections in head and neck carcinogenesis. Head Neck Pathol 2012;6 Suppl 1:S3-15.
  20. Mork J, Møller B, Dahl T, Bray F. Time trends in pharyngeal cancer incidence in Norway 1981-2005: a subsite analysis based on a reabstraction and recoding of registered cases. Cancer Causes Control 2010;21(9):1397-405.
  21. Hammarstedt L, Lindquist D, Dahlstrand H, Romanitan M, Dahlgren LO, Joneberg J, et al. Human papillomavirus as a risk factor for the increase in incidence of tonsillar cancer. Int J Cancer 2006;119(11):2620-3.
  22. Fossum GH, Lie AK, Jebsen P, Sandlie LE, Mork J. Human papillomavirus in oropharyngeal squamous cell carcinoma in South-Eastern Norway: prevalence, genotype, and survival. Eur Arch Otorhinolaryngol 2017;274(11):4003-10.
  23. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010;363(1):24-35.
  24. Nygård M, Aagnes B, Bray F, Møller B, Mork J. Population-based evidence of increased survival in human papillomavirus-related head and neck cancer. Eur J Cancer 2012;48(9):1341-6.
  25. Marur S, Lee JW, Cmelak A, Zhao W, Westra WH, Chung CH, et al. ECOG 1308: A phase II trial of induction chemotherapy followed by cetuximab with low dose versus standard dose IMRT in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx (OP). J Clin Oncol 2012;30(15 SUPPL. 1):5566
  26. Mehanna H, Robinson M, Hartley A, Kong A, Foran B, Fulton-Lieuw T, et al. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. Lancet 2019;393(10166):51-60.
  27. Cmelak A, Li S, Marur S, Zhao W, Westra WH, Chung CH, et al. E1308: Reduced-dose IMRT in human papilloma virus (HPV)-associated resectable oropharyngeal squamous carcinomas (OPSCC) after clinical complete response (CCR) to induction chemotherapy (IC). J Clin Oncol 2014;32(18 SUPPL. 1):LBA6006.
  28. O'Sullivan B, Huang SH, Siu LL, Waldron J, Zhao H, Perez-Ordonez B, et al. Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis. J Clin Oncol 2013;31(5):543-50.
  29. Samuels SE, Vainshtein J, Spector ME, Ibrahim M, McHugh JB, Tao Y, et al. Impact of retropharyngeal adenopathy on distant control and survival in HPV-related oropharyngeal cancer treated with chemoradiotherapy. Radiother Oncol 2015;116(1):75-81.
  30. Lacchetti C, Waldron J, Perez-Ordonez B, Kamel-Reid S, Cripps C, Gilbert R. Routine Human Papilloma Virus (HPV) Testing in Squamous Cell Head and Neck Cancer. Toronto: Cancer Care Ontario; 2013. Evidence-Based Series 5-9 IN REVIEW. Tilgjengelig fra: https://www.cancercareontario.ca/en/guidelines-advice/types-of-cancer/581 
  31. Friborg JT, Melbye M. Cancer patterns in Inuit populations. Lancet Oncol 2008;9(9):892-900.
  32. Pantanowotz L, Deeken JF. HIV infection and malignancy: management considerations. UpToDate [Database]. Waltham, MA: UpToDate, Inc [oppdatert 8. januar 2018; lest 14. februar 2018].
  33. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007;370(9581):59-67.
  34. Rusthoven K, Chen C, Raben D, Kavanagh B. Use of external beam radiotherapy is associated with reduced incidence of second primary head and neck cancer: a SEER database analysis. Int J Radiat Oncol Biol Phys 2008;71(1):192-8.
  35. Belsky JL, Tachikawa K, Cihak RW, Yamamoto T. Salivary gland tumors in atomic bomb survivors, Hiroshima-Nagasaki, 1957 to 1970. JAMA 1972;219(7):864-8.
  36. Schneider AB, Lubin J, Ron E, Abrahams C, Stovall M, Goel A, et al. Salivary gland tumors after childhood radiation treatment for benign conditions of the head and neck: dose-response relationships. Radiat Res 1998;149(6):625-30.
  37. Foulkes WD, Brunet JS, Sieh W, Black MJ, Shenouda G, Narod SA. Familial risks of squamous cell carcinoma of the head and neck: retrospective case-control study. BMJ 1996;313(7059):716-21.
  38. Copper MP, Jovanovic A, Nauta JJ, Braakhuis BJ, de Vries N, van der Waal I, et al. Role of genetic factors in the etiology of squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 1995;121(2):157-60.
  39. Riaz N, Morris LG, Lee W, Chan TA. Unraveling the molecular genetics of head and neck cancer through genome-wide approaches. Genes Dis 2014;1(1):75-86.
  40. Chung CH, Parker JS, Karaca G, Wu J, Funkhouser WK, Moore D, et al. Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell 2004;5(5):489-500.
  41. Toustrup K, Sørensen BS, Alsner J, Overgaard J. Hypoxia gene expression signatures as prognostic and predictive markers in head and neck radiotherapy. Semin Radiat Oncol 2012;22(2):119-27.
  42. Danish Head and Neck Cancer Group [nettside]. Aarhus: DAHANCA [oppdatert 2018; lest 14. februar 2018]. Tilgjengelig fra: https://www.dahanca.oncology.dk/ 
  43. Halkjelsvik T, Lund KE, Kraft P, Rise J. Fear appeals in advanced tobacco control environments: the impact of a national mass media campaign in Norway. Health Educ Res 2013;28(5):888-97.
  44. McLaughlin JK, Gridley G, Block G, Winn DM, Preston-Martin S, Schoenberg JB, et al. Dietary factors in oral and pharyngeal cancer. J Natl Cancer Inst 1988;80(15):1237-43.
  45. WCRF International. Mouth, pharynx & larynx cancers: how diet, nutrition and physical activity affect mouth and throat cancer risk. I: Diet, Nutrition, Physical Activity and Cancer: a Global Perspective [nettdokument]. London: World Cancer Research Fund International [oppdatert 2018; lest 19. februar 2020]. Tilgjengelig fra: https://www.wcrf.org/dietandcancer/mouth-pharynx-larynx-cancers 
  46. WCRF International. Nasopharyngeal cancer: how diet, nutrition and physical activity affect nasopharyngeal cancer risk. I: Diet, Nutrition, Physical Activity and Cancer: a Global Perspective [nettdokument]. London: World Cancer Research Fund International [oppdatert 2018; lest 19. februar 2020]. Tilgjengelig fra: https://www.wcrf.org/dietandcancer/nasopharyngeal-cancer 
  47. Hong WK, Lippman SM, Itri LM, Karp DD, Lee JS, Byers RM, et al. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 1990;323(12):795-801.
  48. Klass CM, Shin DM. Current status and future perspectives of chemoprevention in head and neck cancer. Curr Cancer Drug Targets 2007;7(7):623-32.
  49. Lov om pasient- og brukerrettigheter (pasient- og brukerrettighetsloven). LOV-1999-07-02-63. Sist endret: LOV-2018-06-15-38 fra 20.07.2018. Tilgjengelig fra: https://lovdata.no/dokument/NL/lov/1999-07-02-63 
  50. Forskrift om prioritering av helsetjenester, rett til nødvendig helsehjelp fra spesialisthelsetjenesten, rett til behandling i utlandet og om klagenemnd (prioriteringsforskriften). FOR-2000-12-01-1208. Sist endret: FOR-2019-01-11-16 fra 01.02.2019. Tilgjengelig fra: https://lovdata.no/dokument/SF/forskrift/2000-12-01-1208 
  51. Larsen IK, red. Cancer in Norway 2015: cancer incidence, mortality, survival and prevalence in Norway. Oslo: Cancer Registry of Norway; 2016. Tilgjengelig fra: https://www.kreftregisteret.no/globalassets/cancer-in-norway/2015/cin2015-special_issue-web.pdf 
  52. Ursin G, Grimsrud TK. Kan krefttrollet temmes? Svaret er et klart ja [nettartikkel]. Oslo: Afrenposten [oppdatert 27. mars 2017; lest 25. februar 2020]. Tilgjengelig fra: https://www.aftenposten.no/viten/i/9anWl/kan-krefttrollet-temmes-svaret-er-et-klart-ja 
  53. Guidance on cancer services: improving outcomes in head and neck cancers: the manual. London: National Institute for Clinical Excellence; 2004. Tilgjengelig fra: https://www.nice.org.uk/guidance/csg6/resources/improving-outcomes-in-head-and-neck-cancers-update-pdf-773377597 
  54. Shellock R & D Services, Inc, Shellock FG. MRIsafety.com: your information resource for MRI safety, bioeffects & patient management [nettside]. [s.l.]: Shellock R & D Services, Inc. and Frank G. Shelloc [oppdatert 2018; lest 14. desember 2018]. Tilgjengelig fra: http://www.mrisafety.com/ 
  55. Al-Bulushi NK, Abouzied ME. Comparison of 18F-FDG PET/CT scan and 99mTc-MDP bone scintigraphy in detecting bone metastasis in head and neck tumors. Nucl Med Commun 2016;37(6):583-8.
  56. Fujimoto R, Higashi T, Nakamoto Y, Hara T, Lyshchik A, Ishizu K, et al. Diagnostic accuracy of bone metastases detection in cancer patients: comparison between bone scintigraphy and whole-body FDG-PET. Ann Nucl Med 2006;20(6):399-408.
  57. Isles MG, McConkey C, Mehanna HM. A systematic review and meta-analysis of the role of positron emission tomography in the follow up of head and neck squamous cell carcinoma following radiotherapy or chemoradiotherapy. Clin Otolaryngol 2008;33(3):210-22.
  58. Yeung AR, Liauw SL, Amdur RJ, Mancuso AA, Hinerman RW, Morris CG, et al. Lymph node-positive head and neck cancer treated with definitive radiotherapy: can treatment response determine the extent of neck dissection? Cancer 2008;112(5):1076-82.
  59. Langerman A, Plein C, Vokes EE, Salama JK, Haraf DJ, Blair EA, et al. Neck response to chemoradiotherapy: complete radiographic response correlates with pathologic complete response in locoregionally advanced head and neck cancer. Arch Otolaryngol Head Neck Surg 2009;135(11):1133-6.
  60. Leslie A, Fyfe E, Guest P, Goddard P, Kabala JE. Staging of squamous cell carcinoma of the oral cavity and oropharynx: a comparison of MRI and CT in T- and N-staging. J Comput Assist Tomogr 1999;23(1):43-9.
  61. Sigal R, Zagdanski AM, Schwaab G, Bosq J, Auperin A, Laplanche A, et al. CT and MR imaging of squamous cell carcinoma of the tongue and floor of the mouth. Radiographics 1996;16(4):787-810.
  62. Dammann F, Horger M, Mueller-Berg M, Schlemmer H, Claussen CD, Hoffman J, et al. Rational diagnosis of squamous cell carcinoma of the head and neck region: comparative evaluation of CT, MRI, and 18FDG PET. AJR Am J Roentgenol 2005;184(4):1326-31.
  63. Arya S, Rane P, Deshmukh A. Oral cavity squamous cell carcinoma: role of pretreatment imaging and its influence on management. Clin Radiol 2014;69(9):916-30.
  64. Liao LJ, Lo WC, Hsu WL, Wang CT, Lai MS. Detection of cervical lymph node metastasis in head and neck cancer patients with clinically N0 neck-a meta-analysis comparing different imaging modalities. BMC Cancer 2012;12:236.
  65. Wu LM, Xu JR, Liu MJ, Zhang XF, Hua J, Zheng J, et al. Value of magnetic resonance imaging for nodal staging in patients with head and neck squamous cell carcinoma: a meta-analysis. Acad Radiol 2012;19(3):331-40.
  66. Kyzas PA, Evangelou E, Denaxa-Kyza D, Ioannidis JP. 18F-fluorodeoxyglucose positron emission tomography to evaluate cervical node metastases in patients with head and neck squamous cell carcinoma: a meta-analysis. J Natl Cancer Inst 2008;100(10):712-20.
  67. de Bondt RB, Nelemans PJ, Hofman PA, Casselman JW, Kremer B, van Engelshoven JM, et al. Detection of lymph node metastases in head and neck cancer: a meta-analysis comparing US, USgFNAC, CT and MR imaging. Eur J Radiol 2007;64(2):266-72.
  68. Haughey BH, Gates GA, Arfken CL, Harvey J. Meta-analysis of second malignant tumors in head and neck cancer: the case for an endoscopic screening protocol. Ann Otol Rhinol Laryngol 1992;101(2 Pt 1):105-12.
  69. de Bree R, Deurloo EE, Snow GB, Leemans CR. Screening for distant metastases in patients with head and neck cancer. Laryngoscope 2000;110(3 Pt 1):397-401.
  70. Warner GC, Cox GJ. Evaluation of chest radiography versus chest computed tomography in screening for pulmonary malignancy in advanced head and neck cancer. J Otolaryngol 2003;32(2):107-9.
  71. Arunachalam PS, Putnam G, Jennings P, Messersmith R, Robson AK. Role of computerized tomography (CT) scan of the chest in patients with newly diagnosed head and neck cancers. Clin Otolaryngol Allied Sci 2002;27(5):409-11.
  72. Ow TJ, Myers JN. Current management of advanced resectable oral cavity squamous cell carcinoma. Clin Exp Otorhinolaryngol 2011;4(1):1-10.
  73. Lonneux M, Hamoir M, Reychler H, Maingon P, Duvillard C, Calais G, et al. Positron emission tomography with [18F]fluorodeoxyglucose improves staging and patient management in patients with head and neck squamous cell carcinoma: a multicenter prospective study. J Clin Oncol 2010;28(7):1190-5.
  74. Brierley JD, Gospodarwicz MK, Wittekind C, red. TNM : classification of malignant tumours. 8. utg. Oxford: Wiley-Blackwell; 2017.
  75. Talmi YP, Takes RP, Alon EE, Nixon IJ, Lopez F, de Bree R, et al. Prognostic value of lymph node ratio in head and neck squamous cell carcinoma. Head Neck 2018;40(5):1082-90.
  76. Kwon M, Roh JL, Lee J, Cho KJ, Choi SH, Nam SY, et al. Extranodal extension and thickness of metastatic lymph node as a significant prognostic marker of recurrence and survival in head and neck squamous cell carcinoma. J Craniomaxillofac Surg 2015;43(6):769-78.
  77. Wreesmann VB, Katabi N, Palmer FL, Montero PH, Migliacci JC, Gonen M, et al. Influence of extracapsular nodal spread extent on prognosis of oral squamous cell carcinoma. Head Neck 2016;38 Suppl 1:E1192-9.
  78. Faglige anbefalinger for nomenklatur for volumer i stråleterapi. Østerås: Direktoratet for strålevern og atomsikkerhet; 2019. Teknisk dokument nummer 14. Tilgjengelig fra: https://www.dsa.no/filer/88da27347c.pdf 
  79. Grégoire V, Evans M, Le QT, Bourhis J, Budach V, Chen A, et al. Delineation of the primary tumour Clinical Target Volumes (CTV-P) in laryngeal, hypopharyngeal, oropharyngeal and oral cavity squamous cell carcinoma: AIRO, CACA, DAHANCA, EORTC, GEORCC, GORTEC, HKNPCSG, HNCIG, IAG-KHT, LPRHHT, NCIC CTG, NCRI, NRG Oncology, PHNS, SBRT, SOMERA, SRO, SSHNO, TROG consensus guidelines. Radiother Oncol 2018;126(1):3-24.
  80. Gregoire V, Ang K, Budach W, Grau C, Hamoir M, Langendijk JA, et al. Delineation of the neck node levels for head and neck tumors: a 2013 update. DAHANCA, EORTC, HKNPCSG, NCIC CTG, NCRI, RTOG, TROG consensus guidelines. Radiother Oncol 2014;110(1):172-81.
  81. Biau J, Lapeyre M, Troussier I, Budach W, Giralt J, Grau C, et al. Selection of lymph node target volumes for definitive head and neck radiation therapy: a 2019 Update. Radiother Oncol 2019;134:1-9.
  82. Simon C, Caballero C, Gregoire V, Thurnher D, Koivunen P, Ceruse P, et al. Surgical quality assurance in head and neck cancer trials: an EORTC Head and Neck Cancer Group position paper based on the EORTC 1420 "Best of" and 24954 "larynx preservation" study. Eur J Cancer 2018;103:69-77.
  83. Bourhis J, Overgaard J, Audry H, Ang KK, Saunders M, Bernier J, et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet 2006;368(9538):843-54.
  84. Baujat B, Bourhis J, Blanchard P, Overgaard J, Ang KK, Saunders M, et al. Hyperfractionated or accelerated radiotherapy for head and neck cancer. Cochrane Database Syst Rev 2010;(12):CD002026.
  85. Overgaard J, Hansen HS, Specht L, Overgaard M, Grau C, Andersen E, et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet 2003;362(9388):933-40.
  86. Brouwer CL, Steenbakkers RJ, Bourhis J, Budach W, Grau C, Gregoire V, et al. CT-based delineation of organs at risk in the head and neck region: DAHANCA, EORTC, GORTEC, HKNPCSG, NCIC CTG, NCRI, NRG Oncology and TROG consensus guidelines. Radiother Oncol 2015;117(1):83-90.
  87. Kirkpatrick JP, van der Kogel AJ, Schultheiss TE. Radiation dose-volume effects in the spinal cord. Int J Radiat Oncol Biol Phys 2010;76(3 Suppl):S42-9.
  88. Lambrecht M, Eekers DBP, Alapetite C, Burnet NG, Calugaru V, Coremans IEM, et al. Radiation dose constraints for organs at risk in neuro-oncology; the European Particle Therapy Network consensus. Radiother Oncol 2018;128(1):26-36.
  89. Mendenhall NP, Li Z. Proton therapy. I: Halperin EC, Brady LW, Perez CA, Wazer DE, red. Perez and Bradys principles and practice of radiation oncology. 6. utg. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2013.
  90. Pommier P, Combs SE, Kamada T. Carbon Ions. I: Halperin EC, Brady LW, Perez CA, Wazer DE, red. Perez and Bradys principles and practice of radiation oncology. 6. utg. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2013.
  91. Furness S, Glenny AM, Worthington HV, Pavitt S, Oliver R, Clarkson JE, et al. Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy. Cochrane Database Syst Rev 2011;(4):CD006386.
  92. Pignon JP, Bourhis J, Domenge C, Designé L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000;355(9208):949-55.
  93. Pignon JP, le Maître A, Maillard E, Bourhis J, MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009;92(1):4-14.
  94. Blanchard P, Bourhis J, Lacas B, Posner MR, Vermorken JB, Cruz Hernandez JJ, et al. Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group. J Clin Oncol 2013;31(23):2854-60.
  95. Noronha V, Joshi A, Patil VM, Agarwal J, Laskar SG, Budrukkar AN, et al. Phase III randomized trial comparing weekly versus three-weekly (W3W) cisplatin in patients receiving chemoradiation for locally advanced head and neck cancer. J Clin Oncol 2017;35(15 suppl):6007.
  96. Szturz P, Wouters K, Kiyota N, Tahara M, Prabhash K, Noronha V, et al. Weekly Low-Dose Versus Three-Weekly High-Dose Cisplatin for Concurrent Chemoradiation in Locoregionally Advanced Non-Nasopharyngeal Head and Neck Cancer: A Systematic Review and Meta-Analysis of Aggregate Data. Oncologist 2017;22(9):1056-66.
  97. Bernier J, Cooper JS, Pajak TF, van Glabbeke M, Bourhis J, Forastiere A, et al. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck 2005;27(10):843-50.
  98. Hassan Metwally MA, Ali R, Kuddu M, Shouman T, Strojan P, Iqbal K, et al. IAEA-HypoX. A randomized multicenter study of the hypoxic radiosensitizer nimorazole concomitant with accelerated radiotherapy in head and neck squamous cell carcinoma. Radiother Oncol 2015;116(1):15-20.
  99. Overgaard J, Hansen HS, Overgaard M, Bastholt L, Berthelsen A, Specht L, et al. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother Oncol 1998;46(2):135-46.
  100. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354(6):567-78.
  101. Mehanna H, Kong A, Hartley A, Mistry P, Dalby M, Fulton-Lieuw T, et al. Cetuximab versus cisplatin in patients with HPV-positive, low risk oropharyngeal cancer, receiving radical radiotherapy. Presentert på ESMO 2018 Congress i München 22. Oktober 2018. Tilgjengelig fra: https://oncologypro.esmo.org/Meeting-Resources/ESMO-2018-Congress/Cetuximab-versus-cisplatin-in-patients-with-HPV-positive-low-risk-oropharyngeal-cancer-receiving-radical-radiotherapy 
  102. Trotti A, Harris J, Gillison M, Eisbruch A, Harari PM, Adelstein DJ, et al. NRG-RTOG 1016: Phase III trial comparing radiation/cetuximab to radiation/cisplatin in HPV-related cancer of the oropharynx. Int J Radiat Oncol Biol Phys 2018;102(5):1604-5.
  103. Behandling af planocellulært karcinom i mundhulen: nationale retningslinjer. 3. utg. Aarhus: DAHANCA; 2016.
  104. Head and neck cancers. Version 1.2015. Fort Washington, PA: National Coprehensive Cancer Network; 2015. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines).
  105. Nasjonalt handlingsprogram for palliasjon i kreftomsorgen. Oslo: Helsedirektoratet; 2015. IS-2285. Tilgjengelig fra: https://helsedirektoratet.no/retningslinjer/nasjonalt-handlingsprogram-med-retningslinjer-for-palliasjon-i-kreftomsorgen 
  106. Seneffekter etter kreftbehandling: faglige råd. Oslo: Helsedirektoratet; 2017. IS-2551. Tilgjengelig fra: https://helsedirektoratet.no/publikasjoner/seneffekter-etter-kreft 
  107. DAHANCA 25 studierne – Styrketræning til hoved-halscancer patienter. Aarhus: DAHANCA; u.å. Tilgjengelig fra: https://www.dahanca.oncology.dk/assets/files/GUID_Styrketraening%20til%20hoved-halscancer.pdf 
  108. Gilbert J, Murphy BA, Jackson L. Health-related quality of life in head and neck cancer. UpToDate [Database]. Waltham, MA: UpToDate, Inc [oppdatert 2016; lest 30. juni 2016].
  109. Opfølgningsprogram for hoved- og halskræft. København: Sundhedsstyrelsen; 2015. Tilgjengelig fra: https://www.sst.dk/da/udgivelser/2015/opfoelgningsprogram-for-hoved-og-halskraeft 
  110. Dysfagi - utredning av spise- og svelgefunksjon [nettside]. Bjørnemyr: Sunnaas sykehus [oppdatert 02. mars 2017; lest 16. mars 2018]. Tilgjengelig fra: https://www.sunnaas.no/behandlinger/dysfagi-utredning-av-spise-og-svelgefunksjon 
  111. Galloway T, Amdur R. Management of late complications of head and neck cancer and its treatment. UpToDate [Database]. Waltham, MA: UpToDate, Inc [oppdatert 2016; lest 30. juni 2016].
  112. Munn- og halskreftforeningen [nettside]. Oslo: Munn- og halskreftforeningen [oppdatert 2018; lest 16. februar 2018]. Tilgjengelig fra: http://www.munnoghalskreft.no/ 
  113. Montebello: nytt persoektiv på livet [nettside]. Mesnali: Montebellosenteret [oppdatert 2018; lest 16. februar 2018]. Tilgjengelig fra: https://www.montebellosenteret.no/ 
  114. Nutting CM, Morden JP, Harrington KJ, Urbano TG, Bhide SA, Clark C, et al. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol 2011;12(2):127-36.
  115. Xu J, Cao Y. Radiation-induced carotid artery stenosis: a comprehensive review of the literature. Interventional neurology 2014;2(4):183-92.
  116. Head and neck cancers. Version 2.2018. Fort Washington, PA: National Coprehensive Cancer Network; 2018. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines).
  117. Merino OR, Lindberg RD, Fletcher GH. An analysis of distant metastases from squamous cell carcinoma of the upper respiratory and digestive tracts. Cancer 1977;40(1):145-51.
  118. Chen AM, Farwell DG, Luu Q, Cheng S, Donald PJ, Purdy JA. Prospective trial of high-dose reirradiation using daily image guidance with intensity-modulated radiotherapy for recurrent and second primary head-and-neck cancer. Int J Radiat Oncol Biol Phys 2011;80(3):669-76.
  119. Cacicedo J, Navarro A, Alongi F, Gómez de Iturriaga A, Del Hoyo O, Boveda E, et al. The role of re-irradiation of secondary and recurrent head and neck carcinomas. Is it a potentially curative treatment? A practical approach. Cancer Treat Rev 2014;40(1):178-89.
  120. Wang CC. To reirradiate or not to reirradiate? Int J Radiat Oncol Biol Phys 1994;29(4):913; discussion 9.
  121. Strojan P, Corry J, Eisbruch A, Vermorken JB, Mendenhall WM, Lee AW, et al. Recurrent and second primary squamous cell carcinoma of the head and neck: when and how to reirradiate. Head Neck 2015;37(1):134-50.
  122. Spencer SA, Harris J, Wheeler RH, Machtay M, Schultz C, Spanos W, et al. Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck. Head Neck 2008;30(3):281-8.
  123. De Crevoisier R, Bourhis J, Domenge C, Wibault P, Koscielny S, Lusinchi A, et al. Full-dose reirradiation for unresectable head and neck carcinoma: experience at the Gustave-Roussy Institute in a series of 169 patients. J Clin Oncol 1998;16(11):3556-62.
  124. Kim YS. Reirradiation of head and neck cancer in the era of intensity-modulated radiotherapy: patient selection, practical aspects, and current evidence. Radiat Oncol J 2017;35(1):1-15.
  125. Shahid Iqbal M, Kelly C, Kovarik J, Goranov B, Shaikh G, Morgan D, et al. Palliative radiotherapy for locally advanced non-metastatic head and neck cancer: A systematic review. Radiother Oncol 2018;126(3):558-67.
  126. Agarwal JP, Nemade B, Murthy V, Ghosh-Laskar S, Budrukkar A, Gupta T, et al. Hypofractionated, palliative radiotherapy for advanced head and neck cancer. Radiother Oncol 2008;89(1):51-6.
  127. Corry J, Peters LJ, Costa ID, Milner AD, Fawns H, Rischin D, et al. The 'QUAD SHOT'--a phase II study of palliative radiotherapy for incurable head and neck cancer. Radiother Oncol 2005;77(2):137-42.
  128. Porceddu SV, Rosser B, Burmeister BH, Jones M, Hickey B, Baumann K, et al. Hypofractionated radiotherapy for the palliation of advanced head and neck cancer in patients unsuitable for curative treatment--"Hypo Trial". Radiother Oncol 2007;85(3):456-62.
  129. Maare C, Kjeldsen R, Jensen K, Andersen M, Andersen E, Johansen J. PO-0666: High dose hypofractionated radiotherapy for treatment and palliation of head and neck cancer patients. Radiother Oncol 2014;111(Suppl 1):S8.
  130. Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro G, Jr., et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 2019;394(10212):1915-28.
  131. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359(11):1116-27.
  132. Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA, Eastern Cooperative Oncology Group. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 2005;23(34):8646-54.
  133. Guigay J, Fayette J, Mesia R, Lafond C, Saada-Bouzid E, Geoffrois L, et al. TPExtreme randomized trial: TPEx versus Extreme regimen in 1st line recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). J Clin Oncol 2019;37(15_suppl):6002.
  134. Bentzen JD, Hansen HS. Phase II analysis of paclitaxel and capecitabine in the treatment of recurrent or disseminated squamous cell carcinoma of the head and neck region. Head Neck 2007;29(1):47-51.
  135. Glisson BS, Murphy BA, Frenette G, Khuri FR, Forastiere AA. Phase II Trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck. J Clin Oncol 2002;20(6):1593-9.
  136. Specht L, Larsen SK, Hansen HS. Phase II study of docetaxel and cisplatin in patients with recurrent or disseminated squamous-cell carcinoma of the head and neck. Ann Oncol 2000;11(7):845-9.
  137. Schoffski P, Catimel G, Planting AS, Droz JP, Verweij J, Schrijvers D, et al. Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group. Ann Oncol 1999;10(1):119-22.
  138. Hitt R, Irigoyen A, Cortes-Funes H, Grau JJ, Garcia-Saenz JA, Cruz-Hernandez JJ. Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. Ann Oncol 2012;23(4):1016-22.
  139. DeConti RC, Schoenfeld D. A randomized prospective comparison of intermittent methotrexate, methotrexate with leucovorin, and a methotrexate combination in head and neck cancer. Cancer 1981;48(5):1061-72.
  140. Colevas AD. Systemic Therapy for Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck. J Natl Compr Canc Netw 2015;13(5):e37-48.
  141. Colevas AD. Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2006;24(17):2644-52.
  142. Vermorken JB, Trigo J, Hitt R, Koralewski P, Diaz-Rubio E, Rolland F, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 2007;25(16):2171-7.
  143. Ferris RL. Immunology and Immunotherapy of Head and Neck Cancer. J Clin Oncol 2015;33(29):3293-304.
  144. Ferris RL, Blumenschein G, Jr., Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med 2016;375(19):1856-67.
  145. Nasjonalt handlingsprogram med retningslinjer for palliasjon i kreftomsorgen [nettdokument]. Oslo: Helsedirektoratet [oppdatert 2015; lest 16. februar 2018]. Tilgjengelig fra: http://www.helsebiblioteket.no/Retningslinjer/Palliasjon/Forord 
  146. Ahn PH, Mitra N, Alonso-Basanta M, Palmer JN, Adappa ND, O'Malley BW, Jr., et al. Risk of lymph node metastasis and recommendations for elective nodal treatment in squamous cell carcinoma of the nasal cavity and maxillary sinus: a SEER analysis. Acta Oncol 2016;55(9-10):1107-14.
  147. El-Naggar AK, Chan JKC, Grandis JR, Slootweg PJ, red. WHO classification of head and neck tumors. 4. utg. Lyon: International Agency for Research on Cancer; 2017. WHO Classification of Tumours Volume 9.
  148. Vrionis FD, Kienstra MA, Rivera M, Padhya TA. Malignant tumors of the anterior skull base. Cancer Control 2004;11(3):144-51.
  149. von Buchwald C, Bradley PJ. Risks of malignancy in inverted papilloma of the nose and paranasal sinuses. Curr Opin Otolaryngol Head Neck Surg 2007;15(2):95-8.
  150. Binazzi A, Ferrante P, Marinaccio A. Occupational exposure and sinonasal cancer: a systematic review and meta-analysis. BMC Cancer 2015;15:49.
  151. Li H, Torabi SJ, Yarbrough WG, Mehra S, Osborn HA, Judson B. Association of Human Papillomavirus Status at Head and Neck Carcinoma Subsites With Overall Survival. JAMA Otolaryngol Head Neck Surg 2018;144(6):519-25.
  152. Harabuchi Y, Yamanaka N, Kataura A, Imai S, Kinoshita T, Mizuno F, et al. Epstein-Barr virus in nasal T-cell lymphomas in patients with lethal midline granuloma. Lancet 1990;335(8682):128-30.
  153. Singh N, Eskander A, Huang SH, Curtin H, Bartlett E, Vescan A, et al. Imaging and resectability issues of sinonasal tumors. Expert Rev Anticancer Ther 2013;13(3):297-312.
  154. Loevner LA, Sonners AI. Imaging of neoplasms of the paranasal sinuses. Magn Reson Imaging Clin N Am 2002;10(3):467-93.
  155. Ethmoid sinus tumors; Maxillary sinus. I: Head and neck cancers. Version 2.2018. Fort Washington, PA: National Coprehensive Cancer Network; 2018. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines).
  156. Kræft i næse og bihuler: nationale retningslinjer for udredning, behandling og rehabilitering af patienter med maligne tumorer i cavum nasi, de paranasale bihuler og vestibulum nasi. Aarhus: Dansk Selskab for Hoved- og Hals Onkologi (DSHHO) og Dansk Hoved-hals Cancer Gruppe (DAHANCA) 2017. Tilgjengelig fra: https://www.dahanca.oncology.dk/assets/files/GUID_Sinonasal%20retningslinjer.pdf 
  157. Lund VJ, Clarke PM, Swift AC, McGarry GW, Kerawala C, Carnell D. Nose and paranasal sinus tumours: United Kingdom National Multidisciplinary Guidelines. J Laryngol Otol 2016;130(S2):S111-s8.
  158. Amit M, Abdelmeguid AS, Watcherporn T, Takahashi H, Tam S, Bell D, et al. Induction Chemotherapy Response as a Guide for Treatment Optimization in Sinonasal Undifferentiated Carcinoma. J Clin Oncol 2019;37(6):504-12.
  159. Eloy JA, Vivero RJ, Hoang K, Civantos FJ, Weed DT, Morcos JJ, et al. Comparison of transnasal endoscopic and open craniofacial resection for malignant tumors of the anterior skull base. Laryngoscope 2009;119(5):834-40.
  160. Bentz BG, Bilsky MH, Shah JP, Kraus D. Anterior skull base surgery for malignant tumors: a multivariate analysis of 27 years of experience. Head Neck 2003;25(7):515-20.
  161. Howard DJ, Lund VJ, Wei WI. Craniofacial resection for tumors of the nasal cavity and paranasal sinuses: a 25-year experience. Head Neck 2006;28(10):867-73.
  162. Nishio N, Fujimoto Y, Fujii M, Saito K, Hiramatsu M, Maruo T, et al. Craniofacial Resection for T4 Maxillary Sinus Carcinoma: Managing Cases with Involvement of the Skull Base. Otolaryngol Head Neck Surg 2015;153(2):231-8.
  163. Patel SG, Singh B, Polluri A, Bridger PG, Cantu G, Cheesman AD, et al. Craniofacial surgery for malignant skull base tumors: report of an international collaborative study. Cancer 2003;98(6):1179-87.
  164. Sakata K, Maeda A, Rikimaru H, Ono T, Koga N, Takeshige N, et al. Advantage of Extended Craniofacial Resection for Advanced Malignant Tumors of the Nasal Cavity and Paranasal Sinuses: Long-Term Outcome and Surgical Management. World Neurosurg 2016;89:240-54.
  165. Wong LY, Lam LK, Fan YW, Yuen AP, Wei WI. Outcome analysis of patients with craniofacial resection: Hong Kong experience. ANZ J Surg 2006;76(5):313-7.
  166. König M, Osnes T, Jebsen P, Meling TR. Craniofacial resection of malignant tumors of the anterior skull base: a case series and a systematic review. Acta Neurochir (Wien) 2018;160(12):2339-48.
  167. Iannetti G, Valentini V, Rinna C, Ventucci E, Marianetti TM. Ethmoido-orbital tumors: our experience. J Craniofac Surg 2005;16(6):1085-91.
  168. Akbaba S, Lang K, Held T, Herfarth K, Rieber J, Plinkert P, et al. Carbon-ion radiotherapy in accelerated hypofractionated active raster-scanning technique for malignant lacrimal gland tumors: feasibility and safety. Cancer Manag Res 2019;11:1155-66.
  169. DAHANCA Radiotherapy Guidelines. Aarhus: DAHANCA; 2018. Tilgjengelig fra: https://www.dahanca.dk/assets/files/GUID_DAHANCA_Radiotherapy%20guidelines%202018.pdf 
  170. King AD, Ahuja AT, Leung SF, Lam WW, Teo P, Chan YL, et al. Neck node metastases from nasopharyngeal carcinoma: MR imaging of patterns of disease. Head Neck 2000;22(3):275-81.
  171. Ho FC, Tham IW, Earnest A, Lee KM, Lu JJ. Patterns of regional lymph node metastasis of nasopharyngeal carcinoma: a meta-analysis of clinical evidence. BMC Cancer 2012;12:98.
  172. NORDCAN prosjektet [nettressurs]. [s.l.]: Association of the Nordic Cancer Registries [oppdatert 20. desember 2017 lest 14. februar 2018]. Tilgjengelig fra: http://www-dep.iarc.fr/nordcan.htm 
  173. Wang WY, Twu CW, Chen HH, Jiang RS, Wu CT, Liang KL, et al. Long-term survival analysis of nasopharyngeal carcinoma by plasma Epstein-Barr virus DNA levels. Cancer 2013;119(5):963-70.
  174. King AD, Bhatia KS. Magnetic resonance imaging staging of nasopharyngeal carcinoma in the head and neck. World journal of radiology 2010;2(5):159-65.
  175. Abdel Khalek Abdel Razek A, King A. MRI and CT of nasopharyngeal carcinoma. AJR Am J Roentgenol 2012;198(1):11-8.
  176. King AD, Ma BB, Yau YY, Zee B, Leung SF, Wong JK, et al. The impact of 18F-FDG PET/CT on assessment of nasopharyngeal carcinoma at diagnosis. Br J Radiol 2008;81(964):291-8.
  177. Lee AW, Ng WT, Pan JJ, Poh SS, Ahn YC, AlHussain H, et al. International guideline for the delineation of the clinical target volumes (CTV) for nasopharyngeal carcinoma. Radiother Oncol 2018;126(1):25-36.
  178. Zhang Y, Chen L, Hu GQ, Zhang N, Zhu XD, Yang KY, et al. Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma. N Engl J Med 2019;381(12):1124-35.
  179. Hashibe M, Brennan P, Chuang SC, Boccia S, Castellsague X, Chen C, et al. Interaction between tobacco and alcohol use and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. Cancer Epidemiol Biomarkers Prev 2009;18(2):541-50.
  180. Ndiaye C, Mena M, Alemany L, Arbyn M, Castellsagué X, Laporte L, et al. HPV DNA, E6/E7 mRNA, and p16INK4a detection in head and neck cancers: a systematic review and meta-analysis. Lancet Oncol 2014;15(12):1319-31.
  181. Weissman JL, Carrau RL. "Puffed-cheek" CT improves evaluation of the oral cavity. AJNR Am J Neuroradiol 2001;22(4):741-4.
  182. Bataini JP, Bernier J, Asselain B, Lave C, Jaulerry C, Brunin F, et al. Primary radiotherapy of squamous cell carcinoma of the oropharynx and pharyngolarynx: tentative multivariate modelling system to predict the radiocurability of neck nodes. Int J Radiat Oncol Biol Phys 1988;14(4):635-42.
  183. O'Sullivan B, Warde P, Grice B, Goh C, Payne D, Liu FF, et al. The benefits and pitfalls of ipsilateral radiotherapy in carcinoma of the tonsillar region. Int J Radiat Oncol Biol Phys 2001;51(2):332-43.
  184. Candela FC, Kothari K, Shah JP. Patterns of cervical node metastases from squamous carcinoma of the oropharynx and hypopharynx. Head Neck 1990;12(3):197-203.
  185. Holmes BJ, Wenig BM. Virus-associated carcinomas of the head & neck: Update from the 2017 WHO classification. Ann Diagn Pathol 2019;38:29-42.
  186. Lewis JS, Jr., Beadle B, Bishop JA, Chernock RD, Colasacco C, Lacchetti C, et al. Human Papillomavirus Testing in Head and Neck Carcinomas: Guideline From the College of American Pathologists. Arch Pathol Lab Med 2018;142(5):559-97.
  187. Grønhøj Larsen C, Gyldenløve M, Jensen DH, Therkildsen MH, Kiss K, Norrild B, et al. Correlation between human papillomavirus and p16 overexpression in oropharyngeal tumours: a systematic review. Br J Cancer 2014;110(6):1587-94.
  188. Hannisdal K, Boysen M, Evensen JF. Different prognostic indices in 310 patients with tonsillar carcinomas. Head Neck 2003;25(2):123-31.
  189. Trotta BM, Pease CS, Rasamny JJ, Raghavan P, Mukherjee S. Oral cavity and oropharyngeal squamous cell cancer: key imaging findings for staging and treatment planning. Radiographics 2011;31(2):339-54.
  190. Corvo R. Evidence-based radiation oncology in head and neck squamous cell carcinoma. Radiother Oncol 2007;85(1):156-70.
  191. Huang SH, Waldron J, Bratman SV, Su J, Kim J, Bayley A, et al. Re-evaluation of Ipsilateral Radiation for T1-T2N0-N2b Tonsil Carcinoma at the Princess Margaret Hospital in the Human Papillomavirus Era, 25 Years Later. Int J Radiat Oncol Biol Phys 2017;98(1):159-69.
  192. Beitler JJ, Zhang Q, Fu KK, Trotti A, Spencer SA, Jones CU, et al. Final results of local-regional control and late toxicity of RTOG 9003: a randomized trial of altered fractionation radiation for locally advanced head and neck cancer. Int J Radiat Oncol Biol Phys 2014;89(1):13-20.
  193. Raghavan U, Quraishi S, Bradley PJ. Multiple primary tumors in patients diagnosed with hypopharyngeal cancer. Otolaryngol Head Neck Surg 2003;128(3):419-25.
  194. Watkinson JC, Clarke RW, red. Scott-Brown's Otorhinolaryngology and Head and Neck Surgery: Volume 3: Head and Neck Surgery, Plastic Surgery. 8. utg. Boca Raton: CRC Press; 2018.
  195. Larsen IK, red. Cancer in Norway 2013: cancer incidence, mortality, survival and prevalence in Norway. Oslo: Cancer Registry of Norway; 2015. Tilgjengelig fra: https://www.kreftregisteret.no/globalassets/cancer-in-norway/2013/cin_2013.pdf 
  196. Watanabe A, Taniguchi M, Tsujie H, Hosokawa M, Fujita M, Sasaki S. The value of narrow band imaging for early detection of laryngeal cancer. Eur Arch Otorhinolaryngol 2009;266(7):1017-23.
  197. Kaanders JH, Hordijk GJ, Dutch Cooperative Head and Neck Oncology Group. Carcinoma of the larynx: the Dutch national guideline for diagnostics, treatment, supportive care and rehabilitation. Radiother Oncol 2002;63(3):299-307.
  198. Becker M, Zbären P, Casselman JW, Kohler R, Dulguerov P, Becker CD. Neoplastic invasion of laryngeal cartilage: reassessment of criteria for diagnosis at MR imaging. Radiology 2008;249(2):551-9.
  199. Mahler V, Boysen M, Brøndbo K. Radiotherapy or CO(2) laser surgery as treatment of T(1a) glottic carcinoma? Eur Arch Otorhinolaryngol 2010;267(5):743-50.
  200. Brøndbo K, Boysen M, Natvig K. Laserkirurgi ved larynxcancer (T1a glottis). Nytt behandlingsalternativ. Tidsskr Nor Legeforen 1997;117(28):4070-1.
  201. Brøndbo K, Fridrich K, Boysen M. Laser surgery of T1a glottic carcinomas; significance of resection margins. Eur Arch Otorhinolaryngol 2007;264(6):627-30.
  202. Ambrosch P. The role of laser microsurgery in the treatment of laryngeal cancer. Curr Opin Otolaryngol Head Neck Surg 2007;15(2):82-8.
  203. Brandstorp-Boesen J, Sørum Falk R, Folkvard Evensen J, Boysen M, Brøndbo K. Risk of Recurrence in Laryngeal Cancer. PLoS One 2016;11(10):e0164068.
  204. Brandstorp-Boesen J, Sørum Falk R, Boysen M, Brøndbo K. Impact of stage, management and recurrence on survival rates in laryngeal cancer. PLoS One 2017;12(7):e0179371.
  205. Brandstorp-Boesen J, Falk RS, Boysen M, Brøndbo K. Long-term trends in gender, T-stage, subsite and treatment for laryngeal cancer at a single center. Eur Arch Otorhinolaryngol 2014;271(12):3233-9.
  206. Skálová A, Stenman G, Simpson RHW, Hellquist H, Slouka D, Svoboda T, et al. The Role of Molecular Testing in the Differential Diagnosis of Salivary Gland Carcinomas. Am J Surg Pathol 2018;42(2):e11-e27.
  207. Saku T, Hayashi Y, Takahara O, Matsuura H, Tokunaga M, Tokunaga M, et al. Salivary gland tumors among atomic bomb survivors, 1950-1987. Cancer 1997;79(8):1465-75.
  208. Tumours of the Salivary Glands. I: Barnes L, Eveson JW, Reichart P, Sidransky D, red. Pathology and genetics of head and neck tumours. Lyon: IARC Press; 2005. s. 209-82.
  209. Shebl FM, Bhatia K, Engels EA. Salivary gland and nasopharyngeal cancers in individuals with acquired immunodeficiency syndrome in United States. Int J Cancer 2010;126(10):2503-8.
  210. Fakhry N, Santini L, Lagier A, Dessi P, Giovanni A. Fine needle aspiration cytology and frozen section in the diagnosis of malignant parotid tumours. Int J Oral Maxillofac Surg 2014;43(7):802-5.
  211. Gnepp DR, Henley D, Simpson R, Eveson R. Salivary and lacrimal glands. I: Gnepp DR, red. Diagnostic surgical pathology of the head and neck. 2. utg. Philadelphia: Saunders Elsevier; 2009. s. 413-562.
  212. Cheung RL, Russell AC, Freeman J. Does routine preoperative imaging of parotid tumours affect surgical management decision making? J Otolaryngol Head Neck Surg 2008;37(3):430-4.
  213. Kato H, Kanematsu M, Watanabe H, Mizuta K, Aoki M. Salivary gland tumors of the parotid gland: CT and MR imaging findings with emphasis on intratumoral cystic components. Neuroradiology 2014;56(9):789-95.
  214. Lee YY, Wong KT, King AD, Ahuja AT. Imaging of salivary gland tumours. Eur J Radiol 2008;66(3):419-36.
  215. Sobin LH, Gospodarwicz MK, Wittekind C, red. TNM: classification of malignant tumours. 7. utg. Oxford: Wiley-Blackwell; 2010.
  216. Valstar MH, van den Brekel MW, Smeele LE. Interpretation of treatment outcome in the clinically node-negative neck in primary parotid carcinoma: a systematic review of the literature. Head Neck 2010;32(10):1402-11.
  217. Bhattacharyya N, Fried MP. Nodal metastasis in major salivary gland cancer: predictive factors and effects on survival. Arch Otolaryngol Head Neck Surg 2002;128(8):904-8.
  218. Zbären P, Nuyens M, Caversaccio M, Greiner R, Stauffer E. Postoperative radiation therapy for T1 and T2 primary parotid carcinoma: is it useful? Otolaryngol Head Neck Surg 2006;135(1):140-3.
  219. Terhaard CH. Postoperative and primary radiotherapy for salivary gland carcinomas: indications, techniques, and results. Int J Radiat Oncol Biol Phys 2007;69(2 Suppl):S52-5.
  220. Biau J, Dunet V, Lapeyre M, Simon C, Ozsahin M, Gregoire V, et al. Practical clinical guidelines for contouring the trigeminal nerve (V) and its branches in head and neck cancers. Radiother Oncol 2018;Sep 8. pii: S0167-8140(18)33458-3:[Epub ahead of print].
  221. Lagha A, Chraiet N, Ayadi M, Krimi S, Allani B, Rifi H, et al. Systemic therapy in the management of metastatic or advanced salivary gland cancers. Head Neck Oncol 2012;4:19.
  222. Laurie SA, Ho AL, Fury MG, Sherman E, Pfister DG. Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review. Lancet Oncol 2011;12(8):815-24.
  223. Fan CY, Wang J, Barnes EL. Expression of androgen receptor and prostatic specific markers in salivary duct carcinoma: an immunohistochemical analysis of 13 cases and review of the literature. Am J Surg Pathol 2000;24(4):579-86.
  224. Locati LD, Quattrone P, Bossi P, Marchianò AV, Cantù G, Licitra L. A complete remission with androgen-deprivation therapy in a recurrent androgen receptor-expressing adenocarcinoma of the parotid gland. Ann Oncol 2003;14(8):1327-8.
  225. Bjørndal K, Krogdahl A, Therkildsen MH, Overgaard J, Johansen J, Kristensen CA, et al. Salivary gland carcinoma in Denmark 1990-2005: outcome and prognostic factors. Results of the Danish Head and Neck Cancer Group (DAHANCA). Oral Oncol 2012;48(2):179-85.
  226. Grau C, Johansen LV, Jakobsen J, Geertsen P, Andersen E, Jensen BB. Cervical lymph node metastases from unknown primary tumours. Results from a national survey by the Danish Society for Head and Neck Oncology. Radiother Oncol 2000;55(2):121-9.
  227. Boscolo-Rizzo P, Schroeder L, Romeo S, Pawlita M. The prevalence of human papillomavirus in squamous cell carcinoma of unknown primary site metastatic to neck lymph nodes: a systematic review. Clin Exp Metastasis 2015;32(8):835-45.
  228. Strojan P, Ferlito A, Medina JE, Woolgar JA, Rinaldo A, Robbins KT, et al. Contemporary management of lymph node metastases from an unknown primary to the neck: I. A review of diagnostic approaches. Head Neck 2013;35(1):123-32.
  229. Tanzler ED, Amdur RJ, Morris CG, Werning JW, Mendenhall WM. Challenging the need for random directed biopsies of the nasopharynx, pyriform sinus, and contralateral tonsil in the workup of unknown primary squamous cell carcinoma of the head and neck. Head Neck 2016;38(4):578-81.
  230. Dale E, Moan JM, Osnes TA, Bogsrud TV. Cervical lymph node metastases of squamous cell carcinoma of unknown origin: the diagnostic value of FDG PET/CT and clinical outcome. Eur Arch Otorhinolaryngol 2017;274(2):1015-9.
  231. López F, Rodrigo JP, Silver CE, Haigentz M, Jr., Bishop JA, Strojan P, et al. Cervical lymph node metastases from remote primary tumor sites. Head Neck 2016;38 Suppl 1:E2374-85.
  232. Prowse SJ, Shaw R, Ganeshan D, Prowse PM, Hanlon R, Lewis-Jones H, et al. The added value of 18F-fluorodeoxyglucose positron emission tomography computed tomography in patients with neck lymph node metastases from an unknown primary malignancy. J Laryngol Otol 2013;127(8):780-7.
  233. Lee JR, Kim JS, Roh JL, Lee JH, Baek JH, Cho KJ, et al. Detection of occult primary tumors in patients with cervical metastases of unknown primary tumors: comparison of (18)F FDG PET/CT with contrast-enhanced CT or CT/MR imaging-prospective study. Radiology 2015;274(3):764-71.
  234. Cianchetti M, Mancuso AA, Amdur RJ, Werning JW, Kirwan J, Morris CG, et al. Diagnostic evaluation of squamous cell carcinoma metastatic to cervical lymph nodes from an unknown head and neck primary site. Laryngoscope 2009;119(12):2348-54.
  235. Rusthoven KE, Koshy M, Paulino AC. The role of fluorodeoxyglucose positron emission tomography in cervical lymph node metastases from an unknown primary tumor. Cancer 2004;101(11):2641-9.
  236. Yoo J, Henderson S, Walker-Dilks C. Evidence-based guideline recommendations on the use of positron emission tomography imaging in head and neck cancer. Clin Oncol (R Coll Radiol) 2013;25(4):e33-66.
  237. Lydiatt WM, Patel SG, O'Sullivan B, Brandwein MS, Ridge JA, Migliacci JC, et al. Head and Neck cancers-major changes in the American Joint Committee on cancer eighth edition cancer staging manual. CA Cancer J Clin 2017;67(2):122-37.
  238. Strojan P, Ferlito A, Langendijk JA, Corry J, Woolgar JA, Rinaldo A, et al. Contemporary management of lymph node metastases from an unknown primary to the neck: II. a review of therapeutic options. Head Neck 2013;35(2):286-93.
  239. Müller von der Grün J, Tahtali A, Ghanaati S, Rödel C, Balermpas P. Diagnostic and treatment modalities for patients with cervical lymph node metastases of unknown primary site – current status and challenges. Radiat Oncol 2017;12(1):82.
  240. Frank SJ, Rosenthal DI, Petsuksiri J, Ang KK, Morrison WH, Weber RS, et al. Intensity-modulated radiotherapy for cervical node squamous cell carcinoma metastases from unknown head-and-neck primary site: M. D. Anderson Cancer Center outcomes and patterns of failure. Int J Radiat Oncol Biol Phys 2010;78(4):1005-10.
  241. Martin JM, Galloway TJ. Evaluation and management of head and neck squamous cell carcinoma of unknown primary. Surg Oncol Clin N Am 2015;24(3):579-91.
  242. Cheraghlou S, Torabi SJ, Husain ZA, Otremba MD, Osborn HA, Mehra S, et al. HPV status in unknown primary head and neck cancer: Prognosis and treatment outcomes. Laryngoscope 2018.
  243. Lindberg R. Distribution of cervical lymph node metastases from squamous cell carcinoma of the upper respiratory and digestive tracts. Cancer 1972;29(6):1446-9.
  244. Pathak I, O'Brien CJ, Petersen-Schaeffer K, McNeil EB, McMahon J, Quinn MJ, et al. Do nodal metastases from cutaneous melanoma of the head and neck follow a clinically predictable pattern? Head Neck 2001;23(9):785-90.
  245. Leong SP. Role of selective sentinel lymph node dissection in head and neck melanoma. J Surg Oncol 2011;104(4):361-8.
  246. Kolk A, Wolff KD, Smeets R, Kesting M, Hein R, Eckert AW. Melanotic and non-melanotic malignancies of the face and external ear - A review of current treatment concepts and future options. Cancer Treat Rev 2014;40(7):819-37.
  247. Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppfølging av maligne melanomer. 8. utg. Oslo: Helsedirektoratet; 2019. IS-2853. Tilgjengelig fra: https://www.helsedirektoratet.no/retningslinjer/maligne-melanomer-handlingsprogram 
  248. Xing Y, Bronstein Y, Ross MI, Askew RL, Lee JE, Gershenwald JE, et al. Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis. J Natl Cancer Inst 2011;103(2):129-42.
  249. Oppfølging og etterkontroll etter avsluttet kurativ behandling I: Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppfølging av maligne melanomer 6. utg. Oslo: Helsedirektoratet; 2017. Tilgjengelig fra: https://www.helsebiblioteket.no/retningslinjer/maligne-melanomer/oppfølging_og_kontroll
  250. Roscher I, Brevig T, Mørk G, Helsing P, Gjersvik P. Mohs’ kirurgi ved basalcellekarsinom i ansiktet. Tidsskr Nor Lægeforen 2011;131(24):2475-9.
  251. Breuninger H, Dietz K. Prediction of subclinical tumor infiltration in basal cell carcinoma. J Dermatol Surg Oncol 1991;17(7):574-8.
  252. Telfer NR, Colver GB, Morton CA. Guidelines for the management of basal cell carcinoma. Br J Dermatol 2008;159(1):35-48.
  253. Khan L, Choo R, Breen D, Assaad D, Fialkov J, Antonyshyn O, et al. Recommendations for CTV margins in radiotherapy planning for non melanoma skin cancer. Radiother Oncol 2012;104(2):263-6.
  254. Amols HI, Lagueux B, Cagna D. Radiobiological effectiveness (RBE) of megavoltage X-ray and electron beams in radiotherapy. Radiat Res 1986;105(1):58-67.
  255. Ganti AK, Kessinger A. Systemic therapy for disseminated basal cell carcinoma: an uncommon manifestation of a common cancer. Cancer Treat Rev 2011;37(6):440-3.
  256. Cowey CL. Targeted therapy for advanced Basal-cell carcinoma: vismodegib and beyond. Dermatol Ther (Heidelb) 2013;3(1):17-31.
  257. Von Hoff DD, LoRusso PM, Rudin CM, Reddy JC, Yauch RL, Tibes R, et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med 2009;361(12):1164-72.
  258. Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med 2012;366(23):2171-9.
  259. Govers TM, Hannink G, Merkx MA, Takes RP, Rovers MM. Sentinel node biopsy for squamous cell carcinoma of the oral cavity and oropharynx: a diagnostic meta-analysis. Oral Oncol 2013;49(8):726-32.
  260. DeConti RC. Chemotherapy of squamous cell carcinoma of the skin. Semin Oncol 2012;39(2):145-9.
  261. Maubec E, Petrow P, Scheer-Senyarich I, Duvillard P, Lacroix L, Gelly J, et al. Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J Clin Oncol 2011;29(25):3419-26.
  262. Study of Pembrolizumab (MK-3475) in Adults With Recurrent/Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) or Locally Advanced Unresectable cSCC (MK-3475-629/KEYNOTE-629) [pågående studie]. 2017-2022. NCT03284424. Tilgjengelig fra: https://clinicaltrials.gov/ct2/show/NCT03284424 
  263. Wong SL, Balch CM, Hurley P, Agarwala SS, Akhurst TJ, Cochran A, et al. Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. J Clin Oncol 2012;30(23):2912-8.
  264. Merkel Cell Carcinoma Stages [nettdokument]. Atlanta, GA: American Cancer Society [oppdatert 9. oktober 2018; lest 17. desember 2018]. Tilgjengelig fra: https://www.cancer.org/cancer/merkel-cell-skin-cancer/detection-diagnosis-staging/staging.html 
  265. Wang TS, Byrne PJ, Jacobs LK, Taube JM. Merkel cell carcinoma: update and review. Semin Cutan Med Surg 2011;30(1):48-56.
  266. Halperin EC, Wazer DE, Perez CA, Brady LW. Perez and Brady's principles and practice of radiation oncology. 6. utg. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins; 2013.
  267. Nicolaidou E, Mikrova A, Antoniou C, Katsambas AD. Advances in Merkel cell carcinoma pathogenesis and management: a recently discovered virus, a new international consensus staging system and new diagnostic codes. Br J Dermatol 2012;166(1):16-21.
  268. Kaufman HL, Russell J, Hamid O, Bhatia S, Terheyden P, D'Angelo SP, et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol 2016;17(10):1374-85.
  269. Clark RR, Soutar DS, Hunter KD. A retrospective analysis of histological prognostic factors for the development of lymph node metastases from auricular squamous cell carcinoma. Histopathology 2010;57(1):138-46.
  270. Lucke A. Die Lehre von den Geschwülsten in anatomischer und klinischer Beziehung  I: Pitha V, Billroth, red. Handbuch der allgemeinen und speciellen chirurgie. Erlangen: Verlag von Ferdinand Enke; 1869.
  271. Patel SG, Prasad ML, Escrig M, Singh B, Shaha AR, Kraus DH, et al. Primary mucosal malignant melanoma of the head and neck. Head Neck 2002;24(3):247-57.
  272. Collins B, Abernethy J, Barnes L. Oral Malignant Melanoma [nettdokument]. Newport Beach, Ca: Oral Cancer Foundation [oppdatert 2010; lest 22. februar 2018]. Tilgjengelig fra: https://oralcancerfoundation.org/facts/rare/oral-malignant-melanoma/ 
  273. Koto M, Demizu Y, Saitoh JI, Suefuji H, Tsuji H, Okimoto T, et al. Multicenter Study of Carbon-Ion Radiation Therapy for Mucosal Melanoma of the Head and Neck: Subanalysis of the Japan Carbon-Ion Radiation Oncology Study Group (J-CROS) Study (1402 HN). Int J Radiat Oncol Biol Phys 2017;97(5):1054-60.
  274. Dulguerov P, Allal AS, Calcaterra TC. Esthesioneuroblastoma: a meta-analysis and review. Lancet Oncol 2001;2(11):683-90.
  275. Brady LW, Perez CA, red. Principles and practice of radiation oncology. 3. utg. Philadelphia: Lippincott-Ravens; 1998.
  276. Tajudeen BA, Arshi A, Suh JD, St John M, Wang MB. Importance of tumor grade in esthesioneuroblastoma survival: a population-based analysis. JAMA Otolaryngol Head Neck Surg 2014;140(12):1124-9.
  277. Patel SG, Singh B, Stambuk HE, Carlson D, Bridger PG, Cantu G, et al. Craniofacial surgery for esthesioneuroblastoma: report of an international collaborative study. J Neurol Surg B Skull Base 2012;73(3):208-20.
  278. König M, Osnes T, Jebsen P, Evensen JF, Meling TR. Olfactory neuroblastoma: a single-center experience. Neurosurg Rev 2018;41(1):323-31.
  279. Frierson HF, Jr., Mills SE, Fechner RE, Taxy JB, Levine PA. Sinonasal undifferentiated carcinoma. An aggressive neoplasm derived from schneiderian epithelium and distinct from olfactory neuroblastoma. Am J Surg Pathol 1986;10(11):771-9.
  280. Kim BS, Vongtama R, Juillard G. Sinonasal undifferentiated carcinoma: case series and literature review. Am J Otolaryngol 2004;25(3):162-6.
  281. Lopez F, Suárez V, Vivanco B, Suarez C, Llorente JL. Current management of sinonasal undifferentiated carcinoma. Rhinology 2015;53(3):212-20.
  282. Mourad WF, Hauerstock D, Shourbaji RA, Hu KS, Culliney B, Li Z, et al. Trimodality management of sinonasal undifferentiated carcinoma and review of the literature. Am J Clin Oncol 2013;36(6):584-8.
  283. Gray ST, Herr MW, Sethi RK, Diercks G, Lee L, Curry W, et al. Treatment outcomes and prognostic factors, including human papillomavirus, for sinonasal undifferentiated carcinoma: a retrospective review. Head Neck 2015;37(3):366-74.
  284. Al-Mamgani A, van Rooij P, Mehilal R, Tans L, Levendag PC. Combined-modality treatment improved outcome in sinonasal undifferentiated carcinoma: single-institutional experience of 21 patients and review of the literature. Eur Arch Otorhinolaryngol 2013;270(1):293-9.
  285. Bossi P, Saba NF, Vermorken JB, Strojan P, Pala L, de Bree R, et al. The role of systemic therapy in the management of sinonasal cancer: A critical review. Cancer Treat Rev 2015;41(10):836-43.
  286. Chambers KJ, Lehmann AE, Remenschneider A, Dedmon M, Meier J, Gray ST, et al. Incidence and survival patterns of sinonasal undifferentiated carcinoma in the United States. J Neurol Surg B Skull Base 2015;76(2):94-100.
  287. Reiersen DA, Pahilan ME, Devaiah AK. Meta-analysis of treatment outcomes for sinonasal undifferentiated carcinoma. Otolaryngol Head Neck Surg 2012;147(1):7-14.
  288. Nasjonal helseplan (2007-2010). Oslo: Helse- og omsorgsdepartementet; 2006. Særtrykk av St.prp. nr. 1 (2006-2007) kapittel 6. Tilgjengelig fra: http://www.regjeringen.no/upload/HOD/Sykehus/Nasjonal_helseplan_Sartrykk.pdf 
  289. Lov om kommunale helse- og omsorgstjenester m.m. (helse- og omsorgstjenesteloven). LOV-2011-06-24-30. Sist endret: LOV-2018-12-20-113 fra 01.01.2019. Tilgjengelig fra: https://lovdata.no/dokument/NL/lov/2011-06-24-30 
  290. Nasjonal strategi for kreftområdet 2006-2009. Oslo: Helse- og omsorgsdepartementet; 2006. Tilgjengelig fra: https://www.regjeringen.no/globalassets/upload/hod/sykehus/kreftstrategi-2006-2009.pdf 
  291. Sammen - mot kreft: nasjonal kreftstrategi 2013-2017. Oslo: Helse- og omsorgsdepartementet; 2013. Tilgjengelig fra: https://www.regjeringen.no/contentassets/07cd14ff763444a3997de1570b85fad1/kreftstrategien_2013.pdf